Cardiff Oncology, Inc.
CRDF
$2.13
$0.094.41%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -17.31% | -24.87% | -21.44% | -9.63% | -5.34% |
| Total Depreciation and Amortization | -4.66% | 15.01% | 47.06% | 103.02% | 113.91% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 25.34% | 41.09% | 20.98% | 16.00% | -0.96% |
| Change in Net Operating Assets | -30.34% | -23.31% | -85.40% | -57.86% | 10.39% |
| Cash from Operations | -22.16% | -30.50% | -42.64% | -22.04% | -4.31% |
| Capital Expenditure | 50.00% | 93.55% | 100.00% | 86.25% | 86.44% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -121.22% | -167.14% | -116.08% | -62.45% | -24.54% |
| Cash from Investing | -121.49% | -167.97% | -116.39% | -62.07% | -23.19% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 360.97% | 2,284.20% | 50,064.49% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 360.97% | 2,284.20% | 50,064.49% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -32.26% | -340.00% | 49.33% | 461.70% | 37.00% |